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Abstract
Higher serum phosphorous is associated with cerebral small vessel disease, an important
driver of cognitive decline and dementia. Whether serum phosphorous, a potentially modifi-
able parameter, associates with risk of incident dementia is not known. We aimed to exam-
ine the association between serum phosphorous and risk of incident dementia and to
determine if the association is modified by age. We used the United States Department of
Veterans Affairs national databases to build a longitudinal observational cohort of US veter-
ans without prior history of dementia and with at least one outpatient serum phosphorus
between October 2008 and September 2010 and followed them until September 2014.
Serum phosphorus was categorized into quintiles:2.9, >2.9 to3.2, >3.2 to3.5, >3.5 to
3.9, >3.9 mg/dL. There were 744,235 participants in the overall cohort. Over a median fol-
low-up of 5.07 years (Interquartile range [IQR]: 4.28, 5.63), adjusted Cox models show that
compared to quintile 2, the risk of incident dementia was increased in quintile 4 (Hazard
Ratio [HR] = 1.05; CI = 1.01–1.10) and quintile 5 (HR = 1.14; CI = 1.09–1.20). In cohort par-
ticipants60 years old, the risk of incident dementia was increased in quintile 4 (HR = 1.29;
CI = 1.12–1.49) and 5 (HR = 1.45; CI = 1.26–1.68). In participants > 60 years old, the risk
was not significant in quintile 4, and was attenuated in quintile 5 (HR = 1.10; CI = 1.05–
1.16). Formal interaction analyses showed that the association between phosphorous and
dementia was more pronounced in those younger than 60, and attenuated in those older
than 60 (P for interaction was 0.004 and <0.0001 in quintiles 4 and 5; respectively). We con-
clude that higher serum phosphorous is associated with increased risk of incident dementia.
This association is stronger in younger cohort participants. The identification of serum phos-
phorous as a risk factor for incident dementia has public health relevance and might inform
the design and implementation of risk reduction strategies.
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Introduction
Dementia is a very important public health problem in the general population. It has been
associated with increased mortality, and contributes substantially to rising health care costs
[1]. Although studies have shown that age-adjusted incidence of dementia is decreasing in the
United States, the overall national prevalence of dementia remains substantially high [2, 3]. A
better understanding of potentially modifiable risk factors associated with increased risk of
dementia might inform strategies of reducing its incidence.
Dementia is an increasingly recognized comorbidity in patients with chronic kidney disease
(CKD), a chronic disease state characterized by disturbance in phosphorus homeostasis where
serum phosphorus is often increased [1, 4–8]. Recent observations by Murray and collabora-
tors who examined risk factors for cognitive impairment in a cross sectional study of 422 com-
munity-dwelling cohort participants with CKD suggest that elevation in serum phosphorus
levels (4.5 mg/dL) was associated with substantial risk of cognitive impairment [9]. Observa-
tions by Wright and collaborators suggest that higher Fibroblast Growth Factor 23 (FGF-23)—
a bone-derived hormone that regulates phosphorus homeostasis and that is often elevated in
patients with CKD—is associated with increased risk of stroke even in patients with normal
kidney function [10]. As elevation of FGF-23 usually precedes that of serum phosphorus, the
authors hypothesized that FGF-23 might be elevated in some patients with normal kidney
function as a response to increased dietary intake of phosphorus and might confer increased
risk of stroke [10]. The same group of investigators also established an association between
FGF-23 and white matter hyperintensities and subclinical brain infarction (both seen on mag-
netic resonance imaging) suggesting a strong association between disordered phosphorus
homeostasis and cerebral small vessel disease which is an important driver of cognitive decline
and dementia [11, 12]. Observations from the Atherosclerosis Risk in Communities (ARIC)
cohort suggest that higher serum phosphorus levels are associated with increased risk of sub-
clinical carotid atherosclerosis and stroke in a general population cohort [13, 14].
Whether serum phosphorus levels are associated with risk of incident dementia has not
been examined in large cohort studies. Given that serum phosphorus is a risk factor for cogni-
tive decline in CKD and that higher FGF-23—often elevated in the context of higher serum
phosphorus—represents a risk factor for cerebral small vessel disease, we hypothesized that
mild elevation in serum phosphorus—even when serum phosphorus levels remain within the
reference range—may be associated with increased risk of incident dementia. Because risk of
dementia increases exponentially with advancing age, we also postulated that if serum phos-
phorus is an independent risk factor for dementia, then the risk of incident dementia would be
modified by age and more pronounced in younger individuals. To test our hypothesis, we
used Department of Veterans Affairs National databases to build a cohort of patients without
dementia at baseline and endeavored to examine the association between serum phosphorus
and risk of incident dementia and formally evaluate potential interaction due to age.
Materials and methods
Patients
Using administrative data from the United States Department of Veterans Affairs (VA), we
identified users of the VA Healthcare System with at least one outpatient serum phosphorus
measurement between October 1, 2008 and September 30, 2010 (n = 930,783), where the date
the first phosphorus measurement was designated as the time of cohort entry (time zero (T0)).
Cohort participants were also required to have at least one outpatient estimated glomerular fil-
tration rate (eGFR) measurement within 1 year prior to T0 as baseline eGFR (n = 836,540).
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Participants were included in the cohort only if their baseline eGFR was 15 mL/min/1.73 m2
and did not receive kidney transplant or dialysis before T0 (n = 762,306). Participants were
excluded if they were diagnosed with dementia, intracranial bleed, or cerebral vascular acci-
dent before T0, yielding an analytic cohort of 744,235. Flow chart for the cohort selection is
depicted in Fig 1. The study (#1163689) was approved by the Institutional Review Board (IRB)
of the VA Saint Louis Health Care System, Saint Louis, MO. A waiver of informed consent was
approved by the IRB.
Data sources
We used the Department of Veterans Affairs databases including inpatient and outpatient
medical SAS datasets (that include utilization data related to all inpatient and outpatient
encounters within the VA system) to ascertain detailed patient demographic characteristics
and comorbidity information based on Current Procedural Terminology (CPT) codes, ICD-
9-CM diagnostic and procedure codes associated with inpatient and outpatient encounters
[15, 16]. The VA Managerial Cost Accounting Laboratory Results file (a comprehensive data-
base that includes VA-wide results for selected laboratory tests obtained in the clinical setting)
provided information on outpatient serum phosphorus and serum creatinine measurements
and other laboratory data. The VA Vital Status and Beneficiary Identification Records Locator
Subsystem (BIRLS) files provided demographic characteristics and death follow-up through
September 30, 2014. The United States Renal Database System (USRDS) data provided infor-
mation on date of first kidney transplant and dialysis services. The VHA’s Corporate Data
Warehouse Vital Signs domains provided data on height and weight to calculate body mass
index. County level socioeconomic data in year 2009 were obtained from the 2014–2015 Area
Health Resources Files (AHRF) system [17].
Primary outcomes
The primary outcome was incident dementia. We used validated case definition for dementia
based on inpatient and outpatient ICD-9-CM diagnostic codes [18, 19]. These ICD-9 codes,
which were validated in population-based studies using administrative health data, had a sensi-
tivity of 69%, specificity of 85%, positive predictive value of 81%, and negative predictive value
of 74% for dementia [18, 19]. Outcomes were ascertained from time of cohort entry (T0) until
September 30, 2014.
Primary predictor
The primary predictor was outpatient serum phosphorus. First phosphorus measurement
between October 1, 2008 and September 30, 2010 was considered the baseline phosphorus.
Patients were grouped into 5 groups based on phosphorus quintiles. Patients with phosphorus
values at quintile cut-points were grouped into the lower quintile (hence not all quintiles are
exactly 20% of the overall cohort).
Covariates
Baseline covariates were captured during the 5-year period preceding cohort entry (T0) and
included baseline eGFR, number of eGFR measurements, number of hospitalizations, age,
race, gender, diabetes mellitus, cardiovascular disease, peripheral artery disease, hypertension,
atrial fibrillation, depression and liver cirrhosis[20, 21]. Race/ethnicity was categorized as
white, black, or other (Latino, Asian, Native American, or other racial/ethnic minority
groups). Comorbidities were assigned on the basis of relevant ICD-9-CM diagnostic and
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procedures codes and CPT codes in the VA Medical SAS datasets as described previously [22–
27]. eGFR was calculated using the abbreviated four-variable Chronic Kidney Disease Epide-
miology Collaboration equation based on age, sex, race, and outpatient serum creatinine [28].
Statistical analysis
Frequencies and proportions for categorical variables, means and standard errors or medians
and interquartile ranges for continuous variables were computed. Adjusted incident rates were
calculated based on Poisson regression given the same age and gender distributions as the
overall cohort. Confidence intervals for incident rates were estimated from normal distribu-
tions. Restricted cubic regression spline analyses were undertaken to characterize the shape of
the relationship between serum phosphorus and risk of dementia. To account for potential
highly influential values, those with serum phosphorus values in the lowest 0.5% and highest
0.5% were excluded from the spline analyses. Hazard ratios of dementia between different
phosphorus quintiles were evaluated from multivariate Cox survival models and quintile 2,
which has the lowest adjusted incident dementia, was selected as the reference group. Cox
model was adjusted for age, race, gender, diabetes mellitus, cardiovascular disease, peripheral
artery disease, hypertension, atrial fibrillation, depression, liver cirrhosis, baseline eGFR, num-
ber of eGFR measurements and number of hospitalizations. Interaction between age and phos-
phorus quintiles was added to detect how age modifies the relationship between phosphorus
and dementia. To evaluate the relationship between phosphorus and dementia in different
Fig 1. Flow chart for cohort selection.
doi:10.1371/journal.pone.0171377.g001
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sub-populations, we built models within patients with age 60 and > 60. In addition, all anal-
yses were additionally run with serum phosphorus deciles as the primary predictor. Patients
who died without dementia during follow up were considered to have experienced competing
risk to dementia and were censored as no dementia at the time of death. We further examined
the association between serum phosphorus and risk of dementia subtypes including risks of
Alzheimer’s disease, vascular dementia, Lewy body dementia and frontotemporal dementia.
Dementia subtypes were defined based on ICD9 codes. In survival analyses, a 95% confidence
interval (CI) of a hazard ratio (HR) that does not include unity was considered statistically sig-
nificant. In all analyses a P-value of 0.05 or less was considered statistically significant. Analy-
ses were performed using SAS Enterprise Guide version 7.1 (SAS Institute, Cary, NC) and R
studio version 0.99.891.
Sensitivity analyses
To evaluate the robustness of the study results, we examined the associations in multiple sensi-
tivity analyses as follows: a. to increase the specificity of the dementia diagnosis, we required
the occurrence of at least 2 ICD-9 codes for dementia in 2 separate clinical encounters (where
sensitivity and specificity have been shown to be 63% and 88%, respectively, and positive pre-
dictive value and negative predictive value were 83% and 72% respectively) [18, 19]; b. to elimi-
nate the effect of Parkinson’s disease on the outcome of dementia, we excluded 2091 patients
with Parkinson’s disease who were included in the primary analysis (N = 742,144); c. We
made different assumptions for relationships between the effect of phosphorus on dementia
and its competing risk death: 1) In order to account for the possibility that the observed rela-
tionship between phosphorus and dementia was due to the effect of phosphorus on death, we
examined the associations in Fine and Gray models where cohort participants who experi-
enced the competing risk were considered to be at risk for dementia after dead,[29] 2) Assum-
ing death informs the occurrence of dementia and patients who experienced death could
also have had dementia, we created a composite outcome of dementia or death, and 3) To
evaluate the relationship only in participants who did not experience the competing risk, we
excluded participants who died before the occurrence of dementia from the cohort yielding an
N = 597,072; d. We additionally built models where we used average serum phosphorus in one
year as baseline phosphorus to account for intra-individual variability in serum phosphorus; e.
where data was available, and to account for potential contribution of neighborhood factors to
the risk of incident dementia, we considered county level characteristics including percentage
with high school diploma (N = 742,741) and percentage below poverty level (N = 737,536) as
covariates in the models; f. we examined the associations in subcohorts where data on body
mass index (N = 727,435), serum calcium (N = 729,274), lipid parameters including HDL-C,
LDL-C, and triglycerides (N = 692,777) were available; g. we included all of the above covari-
ates from models e and f in the models (N = 675,484).
Results
There were 744,235 participants in the overall cohort. The demographic and health character-
istics of the overall cohort and according to quintiles of serum phosphorus levels are described
in Table 1.
Spline analyses depicting the relationship between serum phosphorus and risk of incident
dementia are shown in Fig 2. In analyses considering the entire range of serum phosphorus in
the overall cohort, there was a U-shaped relationship between phosphorus and risk of incident
dementia (Fig 2a). The relationship was not linear in analyses restricted to those with serum
phosphorus levels >2.5mg/dl (the lowest range of normal) (Fig 2b). The relationship was
Phosphorus and dementia
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N (%) 744235 174430 (23.44) 142894 (19.20) 152113 (20.44) 154856 (20.81) 119942 (16.12)
Age (SD) 62.68
(14.52)
63.37 (13.89) 63.78 (14.19) 63.22 (14.55) 62.17 (14.85) 60.35 (15.02)




2.61 (0.30) 3.11 (0.08) 3.40 (0.08) 3.73 (0.11) 4.35 (0.43)




77.05 (21.98) 76.37 (22.55) 76.38 (23.32) 76.14 (24.69) 72.81 (28.43)
Gender Male (%) 693418
(93.17)
166638 (95.53) 135070 (94.52) 141980 (93.34) 141849 (91.60) 107881 (89.94)
Female (%) 50817
(6.83)
7792 (4.47) 7824 (5.48) 10133 (6.66) 13007 (8.40) 12061 (10.06)
Race White (%) 563180
(75.67)
135584 (77.73) 110198 (77.12) 115644 (76.03) 115104 (74.33) 86650 (72.24)
Black (%) 140019
(18.81)
29450 (21.03) 24799 (17.35) 27916 (18.35) 31157 (20.12) 26697 (22.26)
Other (%) 41036
(5.51)
9396 (5.39) 7897 (5.53) 8553 (5.62) 8595 (5.55) 6595 (5.50)
Cardiovascular disease (%) 322651
(43.35)
72487 (41.56) 60665 (42.45) 65710 (43.20) 68367 (44.15) 55422 (46.21)
Diabetes mellitus (%) 332301
(44.65)
71529 (41.01) 60828 (42.57) 67208 (44.18) 71761 (46.34) 60975 (50.84)
Hypertension (%) 613897
(82.49)
142014 (81.42) 117201 (82.02) 125569 (82.55) 128264 (82.83) 100849 (84.08)
Peripheral artery disease (%) 132786
(17.84)
28968 (16.61) 24502 (17.15) 27155 (17.85) 28760 (18.57) 23401 (19.51)
Atrial fibrillation (%) 87102
(11.70)
21081 (12.09) 16754 (11.72) 17337 (11.40) 17709 (11.44) 14221 (11.86)
Depression (%) 108628
(14.60)
25602 (14.68) 19822 (13.87) 21224 (13.95) 22606 (14.06) 19374 (16.15)
Liver cirrhosis (%) 36931
(4.96)
10331 (5.92) 6553 (4.59) 6603 (4.34) 6946 (4.49) 6498 (5.42)




9.45 (8.79) 9.02 (8.38) 8.99 (8.55) 9.18 (8.72) 9.95 (9.76)
Number of hospitalization (SD) 0.64
(1.72)
0.64 (1.70) 0.57 (1.60) 0.57 (1.63) 0.63 (1.69) 0.84 (2.03)




















7.00 (6.82, 7.18) 6.26 (6.07, 6.45) 6.40 (6.21, 6.59) 6.62 (6.43, 6.81) 7.33 (7.10, 7.56)
Years of follow up (IQR)b 5.07
(4.28,
5.63)
5.09 (4.31, 5.63) 5.10 (4.32, 5.63) 5.09 (4.31, 5.63) 5.05 (4.27, 5.63) 4.97 (4.15, 5.60)
Variables for sensitivity analyses
Parkinson’s disease (%) 2091
(0.28)













2.63 (0.27) 3.09 (0.09) 3.38 (0.09) 3.68 (0.08) 4.20 (0.39)
(Continued )
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linear in those with serum phosphorus levels>4.5 mg/dl (Fig 2c). Given the U-shaped rela-
tionship between phosphorus and risk of incident dementia in the overall cohort, we grouped
cohort participant into quintiles, and quintile 2 (where the risk was lowest) was designated as
the reference category.
Association between phosphorus and risk of incident dementia
Over a median duration of follow up of 5.07 years (IQR: 4.28, 5.63), the age and gender
adjusted rate of incident dementia was 6.26 (6.07–6.45), 6.62 (6.43–6.81), and 7.33 (7.10–7.56)
per 1000 person-years in quintile 2 (serum phosphorus > 2.9 and 3.2 mg/dL), quintile 4
(serum phosphorus > 3.5 and 3.9 mg/dL), and quintile 5 (serum phosphorus > 3.9 mg/dL),
respectively. In analyses adjusted for age, race, gender, diabetes mellitus, cardiovascular dis-
ease, peripheral artery disease, hypertension, atrial fibrillation, depression, liver cirrhosis, base-
line eGFR, number of eGFR measurements and number of hospitalizations, we evaluated the
risk of dementia according to serum phosphorus categorized in quintiles. Compared to quin-
tile 2, the risk of incident dementia was increased in quintile 4 (HR = 1.05; CI = 1.01–1.10) and
quintile 5 (HR = 1.14; CI = 1.09–1.20) (Fig 3). We also considered an alternative categorization
























3206 (1.88) 2563 (1.83) 2758 (1.86) 3103 (2.05) 3069 (2.62)
Normal (%) 155036
(21.31)
34237 (20.05) 28552 (20.44) 31484 (21.20) 33516 (22.17) 27247 (23.23)
Overweight (%) 261899
(36.00)
63588 (37.24) 51936 (37.17) 54200 (36.50) 53382 (35.31) 38793 (33.08)
Obesity (%) 295801
(40.66)










9.33 (0.70) 9.35 (0.78) 9.38 (0.49) 9.41 (0.50) 9.41 (0.57)
Lipid panel Number of
patients (%)d















151.05 (136.47) 147.05 (125.34) 146.78 (123.22) 149.54 (126.35) 160.50 (150.18)
Abbreviations: eGFR, estimated glomerular filtration rate; HDL-C, High-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol; SD,
Standard deviation; IQR, Interquartile range; CI, Confidence interval.
a.Incidence per 1000 person-years
b.Calculated from time zero until death occurrence or September 30, 2014
c.Based on phosphorus measurement within one year after first measurement. Quintile cut-points for Average Phosphorus were 2.9, 3.2, 3.5, and 3.8 mg/
dL.
d.Patients with related data available
doi:10.1371/journal.pone.0171377.t001
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Fig 2. Spline analyses for the relationship between serum phosphorus and risk of incident dementia
with serum phosphorus probability distribution histogram represented in gray bars in the
background. Fig 2a: Overall cohort. Fig 2b: Analysis was restricted to cohort participants with serum
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mg/dL), the risk of incident dementia was increased in decile 9 (serum phosphorus > 3.9
and 4.1 mg/dL) [HR = 1.11; CI = 1.04–1.19] and decile 10 (serum phosphorus > 4.1 mg/dL)
[HR = 1.17; CI = 1.10–1.24].
Association of phosphorus and risk of incident dementia is modified by
age
We examined the association between serum phosphorus in quintiles and risk of incident
dementia in cohort participants younger and older than 60 years of age. Compared to quintile
2, the risk of incident dementia for participants 60 years old was increased in quintile 4
(HR = 1.29; CI = 1.12–1.49) and quintile 5 (HR = 1.45; CI = 1.26–1.68) (Fig 4). Risk of
incident dementia for participants > 60 years old was not significant in quintile 4 (HR = 1.03;
CI = 0.98–1.08) and was attenuated but remained significant in quintile 5 (HR = 1.10;
CI = 1.05–1.16) (Fig 4). Formal interaction analyses were undertaken and demonstrated
significant effect modification in that age less than or equal to 60 strengthens the association
between high level serum phosphorus and risk of incident dementia (P for interaction was
0.004 and<0.0001 in quintiles 4 and 5, respectively). We alternatively categorized age into
60, 60–70, and>70, and the results were consistent in that the risk difference between nor-
mal and high phosphorus quintiles was more robust in the youngest group, and was attenuated
with increasing age (S1 Table). Examination of interaction where age was treated as a
Fig 3. Relationship between serum phosphorus (in quintiles) and risk of incident dementia.
doi:10.1371/journal.pone.0171377.g003
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continuous variable yielded consistent results (P value for interaction between age and phos-
phorus quintiles in quintile 4 and 5 were 0.003 and<0.0001, respectively).
Association between serum phosphorus and dementia subtypes
To determine if higher serum phosphorus is associated with a specific subtype of dementia, we
undertook analyses to examine the association of serum phosphorus levels and risk of incident
Alzheimer’s disease, risk of vascular dementia, risk of Lewy body dementia, and risk of fronto-
temporal dementia (Table 2) (Fig 5). The results suggest that higher serum phosphorus levels
were associated with increased risk of Alzheimer’s disease, vascular dementia, and Lewy body
dementia in those younger than 60 years of age. These associations were attenuated and
became non-significant in those older than 60 years of age with notable exception of vascular
dementia where the association was attenuated but remained statistically significant (Table 2).
Fig 4. Relationship between serum phosphorus (in quintiles) and risk of incident dementia by age group (60 and >60). * Indicates significant
interaction (p<0.05) between age group and serum phosphorus in quintiles 4, and 5.
doi:10.1371/journal.pone.0171377.g004
Phosphorus and dementia
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There was no association between serum phosphorus and risk of frontotemporal dementia in
the overall cohort and in analyses stratified by age.
Sensitivity analyses
We evaluated the robustness of the study findings in a number of sensitivity analyses (Table 3)
where we: a. required the occurrence of 2 ICD-9 codes for dementia for disease definition; b.
excluded patients with Parkinson’s disease from the cohort; c. considered death as a competing
risk for dementia outcome where we 1) examined the associations in Fine and Gray models, 2)
created a composite outcome of dementia or death, 3) excluded participants who died before
the occurrence of dementia from cohort; d. to account for potential intra-individual variability
in serum phosphorus, we used average serum phosphorus as a covariate; e. to account for
potential contribution of neighborhood factors to the risk of incident dementia, we considered
county level factors including percentage with high school diploma and percentage below
poverty level as covariates in the models; f. included body mass index, serum calcium, and
lipid parameters including HDL-C, LDL-C, and triglycerides as covariates in the models; g.
included covariates mentioned in e and f in the models. The results of the sensitivity analyses
consistently showed an association between higher serum phosphorus and increased risk of




















1.07 (1.01, 1.13) 1 1.01 (0.95, 1.07) 1.03 (0.97, 1.10) 1.06 (0.98, 1.13)
Age 60 HR
(CI)
1.07 (0.77, 1.50) 1 1.37 (0.98, 1.90) 1.63 (1.19, 2.23) 1.59 (1.15, 2.20)
Age > 60 HR
(CI)





1.09 (1.01, 1.19) 1 1.05 (0.98, 1.13) 1.05 (0.97, 1.13) 1.16 (1.07, 1.26)
Age 60 HR
(CI)
0.77 (0.57, 1.04) 1 1.15 (0.87, 1.52) 1.17 (0.89, 1.53) 1.41 (1.08, 1.85)
Age > 60 HR
(CI)





1.08 (0.94, 1.24) 1 0.96 (0.83, 1.11) 0.94 (0.81, 1.09) 0.98 (0.83, 1.16)
Age 60 HR
(CI)
2.18 (0.92, 5.15) 1 2.28 (0.94, 5.49) 3.38 (1.47, 7.77) 3.20 (1.36, 7.52)
Age > 60 HR
(CI)





0.94 (0.72, 1.24) 1 0.98 (0.74, 1.30) 0.92 (0.69, 1.23) 1.12 (0.82, 1.52)
Age 60 HR
(CI)
0.67 (0.34, 1.35) 1 1.17 (0.62, 2.22) 0.64 (0.30, 1.34) 0.89 (0.44, 1.82)
Age > 60 HR
(CI)
1.00 (0.74, 1.34) 1 0.94 (0.69, 1.29) 1.00 (0.73, 1.36) 1.20 (0.85, 1.68)
Abbreviations: HR, hazard ratio; CI, confidence interval.
Model adjusted for age, race, gender, diabetes mellitus, cardiovascular disease, peripheral artery disease, hypertension, atrial fibrillation, depression, liver
cirrhosis, baseline eGFR, number of eGFR measurements and number of hospitalizations.
Quintile 2 (phosphorus >2.9 and3.2 mg/dl) served as the reference group.
doi:10.1371/journal.pone.0171377.t002
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incident dementia and that the association was more pronounced in cohort participants youn-
ger than 60 years old (Table 3).
Discussion
In this large national cohort of 744,235 veterans, we found that higher serum phosphorus levels
were independently associated with increased risk of incident dementia; this association was
significantly modified by age and was more pronounced in patients less than 60 years old.
This report suggests a novel and potentially modifiable risk factor for incident dementia in
a large cohort of United States veterans. Our results demonstrating that phosphorus is a risk
factor for dementia provide important therapeutic potential and public health relevance. The
American diet is rich in phosphorus [30]. While the recommended dietary allowance for phos-
phorus is 700 mg per day, the actual daily consumption by the average American far exceeds
this amount [31]. Inorganic phosphate is heavily used in processed foods, is often not listed on
food labels, and has high bioavailability. It was reported that 44% of popular grocery items
contained phosphorus additives [32] and this hidden source of phosphorus could contribute
as much as 1000 mg to an individual’s daily phosphorus consumption [33]. Studies have
shown that greater dietary intake of phosphorus results in increased serum phosphorus and
FGF-23 levels and lower dietary intake of phosphorus or consumption of diet where bioavail-
ability of phosphorus is low (vegetarian diet) lowers serum phosphorus and FGF-23 [17, 34–
36]. Whether strategies aimed at reducing phosphorus intake and resultant attenuation of
serum phosphorus levels leads to reduction of dementia risk merits investigation.
Fig 5. Relationship between elevated serum phosphorus (quintile 5) and risk of dementia subtype by age group (60 and >60).
doi:10.1371/journal.pone.0171377.g005
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1.09 (1.02, 1.16) 1 1.02 (0.95, 1.09) 1.03 (0.96, 1.10) 1.12 (1.04, 1.21)
Age 60 HR
(CI)
1.14 (0.84, 1.55) 1 1.34 (0.99, 1.82) 1.51 (1.13, 2.04) 1.74 (1.29, 2.35)
Age > 60 HR
(CI)







1.09 (1.05, 1.14) 1 1.02 (0.98, 1.07) 1.06 (1.02, 1.11) 1.17 (1.11, 1.23)
Age 60 HR
(CI)
1.04 (0.90, 1.20) 1 1.08 (0.93, 1.26) 1.25 (1.08, 1.44) 1.44 (1.25, 1.67)
Age > 60 HR
(CI)
1.10 (1.05, 1.15) 1 1.02 (0.97, 1.06) 1.04 (0.99, 1.09) 1.12 (1.07, 1.19)
Fine & Gray model Overall HR
(CI)
1.09 (1.05, 1.13) 1 1.02 (0.97, 1.06) 1.03 (0.98, 1.07) 1.05 (1.00, 1.10)
Age 60 HR
(CI)
1.05 (0.91, 1.22) 1 1.13 (0.97, 1.31) 1.28 (1.11, 1.48) 1.41 (1.22, 1.62)
Age > 60 HR
(CI)





1.02 (1.00, 1.03) 1 1.05 (1.03, 1.06) 1.16 (1.15, 1.18) 1.48 (1.46, 1.51)
Age 60 HR
(CI)
1.04 (1.00, 1.08) 1 1.05 (1.01, 1.09) 1.16 (1.12, 1.21) 1.57 (1.51, 1.64)
Age > 60 HR
(CI)






1.08 (1.04, 1.12) 1 1.04 (1.00, 1.08) 1.10 (1.05, 1.15) 1.26 (1.21, 1.32)
Age60 HR
(CI)
1.04 (0.90, 1.21) 1 1.13 (0.98, 1.31) 1.30 (1.13, 1.50) 1.51 (1.31, 1.74)
Age>60 HR
(CI)






1.05 (1.01, 1.09) 1 1.04 (1.00, 1.09) 1.05 (1.01, 1.10) 1.10 (1.05, 1.15)
Age 60 HR
(CI)
1.02 (0.87, 1.18) 1 1.20 (1.04, 1.38) 1.39 (1.20, 1.60) 1.50 (1.31, 1.72)
Age > 60 HR
(CI)
1.05 (1.01, 1.10) 1 1.03 (0.99, 1.08) 1.02 (0.97, 1.07) 1.05 (1.00, 1.10)
Additionally control for
education at county
level (N = 742,741)
Overall HR
(CI)
1.09 (1.05, 1.14) 1 1.02 (0.98, 1.07) 1.05 (1.01, 1.10) 1.15 (1.09, 1.20)
Age 60 HR
(CI)
1.05 (0.91, 1.21) 1 1.13 (0.97, 1.31) 1.29 (1.12, 1.49) 1.45 (1.26, 1.68)
Age > 60 HR
(CI)
1.10 (1.05, 1.15) 1 1.01 (0.97, 1.06) 1.03 (0.98, 1.08) 1.10 (1.05, 1.16)
Additionally control for




1.09 (1.05, 1.14) 1 1.02 (0.98, 1.07) 1.06 (1.01, 1.11) 1.15 (1.10, 1.21)
Age 60 HR
(CI)
1.04 (0.90, 1.20) 1 1.14 (0.98, 1.32) 1.30 (1.13, 1.50) 1.45 (1.26, 1.68)
Age > 60 HR
(CI)
1.10 (1.05, 1.15) 1 1.01 (0.97, 1.06) 1.03 (0.99, 1.08) 1.11 (1.05, 1.16)
(Continued )
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Dementia is often considered a disease of old age and risk increases significantly as age
increases. That the relationship between serum phosphorus and risk of incident dementia is
stronger in younger cohort participants (and the corollary observation that risk is attenuated
with increasing age) lends validity to our findings and suggests that the mechanism(s) under-
pinning the association of serum phosphorus and dementia may be different from those of
age-related dementia. An alternative explanation is that risk of dementia substantially
increases with age and in older adults the contribution of age to risk estimates dwarfs other
important but less strong risk factors. In our analyses, we found that higher serum phosphorus
was associated with increased risk of Alzheimer’s disease, vascular dementia, and Lewy body
dementia. Although plausible, our results do not endorse the hypothesis that serum phospho-
rus may be differentially associated with specific subtype of dementia.
In this report, there was a slightly increased risk of incident dementia in quintile 1 of the
overall cohort (those with serum phosphorus  2.9 mg/dL) [HR = 1.09; CI = 1.05–1.14]. In
stratified analyses by age (> 60 and 60 years old), the risk was not increased among cohort


















BMI (N = 727,435)
Overall HR
(CI)
1.09 (1.04, 1.13) 1 1.02 (0.97, 1.06) 1.03 (0.99, 1.08) 1.11 (1.06, 1.16)
Age 60 HR
(CI)
1.05 (0.91, 1.21) 1 1.11 (0.96, 1.29) 1.25 (1.09, 1.44) 1.35 (1.17, 1.56)
Age > 60 HR
(CI)






1.09 (1.04, 1.13) 1 1.02 (0.98, 1.07) 1.06 (1.01, 1.10) 1.15 (1.09, 1.20)
Age60 HR
(CI)
1.04 (0.90, 1.20) 1 1.14 (0.98, 1.33) 1.32 (1.14, 1.52) 1.48 (1.29, 1.71)
Age>60 HR
(CI)







1.10 (1.06, 1.15) 1 1.03 (0.98, 1.08) 1.06 (1.01, 1.10) 1.13 (1.08, 1.19)
Age60 HR
(CI)
1.11 (0.96, 1.30) 1 1.15 (0.99, 1.35) 1.29 (1.11, 1.50) 1.42 (1.22, 1.66)
Age>60 HR
(CI)
1.10 (1.06, 1.15) 1 1.02 (0.97, 1.07) 1.03 (0.99, 1.08) 1.10 (1.04, 1.15)
Additionally control for
BMI, education and







1.10 (1.05, 1.15) 1 1.03 (0.98, 1.08) 1.05 (1.00, 1.09) 1.11 (1.06, 1.17)
Age60 HR
(CI)
1.08 (0.93, 1.26) 1 1.15 (0.98, 1.34) 1.26 (1.09, 1.47) 1.34 (1.15, 1.57)
Age>60 HR
(CI)
1.10 (1.05, 1.15) 1 1.02 (0.97, 1.07) 1.02 (0.98, 1.07) 1.08 (1.02, 1.14)
Abbreviations: BMI, body mass index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HR, hazard ratio; CI,
confidence interval.
Model adjusted for age, race, gender, diabetes mellitus, cardiovascular disease, peripheral artery disease, hypertension, atrial fibrillation, depression, liver
cirrhosis, baseline eGFR, number of eGFR measurements and number of hospitalizations.
Quintile 2 (phosphorus >2.9 and3.2 mg/dl) served as the reference group.
a. Quintile cut-points for Average Phosphorus were 2.9, 3.2, 3.5, and 3.8 mg/dL.
doi:10.1371/journal.pone.0171377.t003
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those older than 60 (1.10; CI = 1.05–1.14). That the association was only significant in those
older than 60 years old may be explained by residual confounding—the notion that older
adults with low serum phosphorus may also have other illnesses (or confounders), both
unmeasured and unknown, that might explain the slight increase in risk in dementia. The
prevalence of malnutrition is very high in the elderly, even in the developed countries [37,
38]. Previous studies have shown that poor nutritional status was significantly associated
with faster cognitive decline [39, 40]. Low phosphorus levels can be a consequence of malnu-
trition and may explain the observed association between low phosphorus and dementia in
those > 60 years old.
To our knowledge, this is the first population-based study evaluating the association
between serum phosphorus levels and the risk of incident dementia. The pathophysiologic
mechanisms underlying the observed association are not clear. Higher serum phosphorus lev-
els are associated with increased risks of cardiovascular events and mortality in patients with
normal kidney function; similar associations have been described in persons who consume a
high phosphorus diet [31, 41–44]. Elevated phosphorus levels have also been shown to be asso-
ciated with increased carotid intima-media thickness independent of traditional atheroscle-
rotic risk factors [13]. In two separate community-based cohorts, subclinical atherosclerotic
calcification was found to be associated with impaired cognitive function and atherosclerotic
disease accounted for significant cognitive impairment [45, 46]. Other reports have suggested
that atherosclerotic carotid disease is not only a major contributor to “vascular” dementia, it
may also play an important role in the pathogenesis of Alzheimer’s disease and other subtypes
of cognitive impairment [5, 47–49]. Increased FGF-23 which occurs in the setting of excess
phosphorus intake may be a mediator or contributor to the observed adverse outcomes [10,
50]. Higher serum phosphorus concentration has been shown in vitro and in vivo to cause
endothelial dysfunction via increased production of reactive oxygen species, decreased nitric
oxide release/availability, increased oxidative stress and inflammatory response, leading to dys-
regulation of vascular tone [51, 52]. Hyperphosphatemia can also induce the release of endo-
thelial membrane-derived microparticles (MPs) which are markers of vascular dysfunction
[53, 54]. These MPs are known to have procoagulant effects and hypercoagulable states have
been linked to cognitive impairment [4].
Our study has several limitations. Due to the observational nature of the study, residual
confounding is a potential limitation and causality cannot be established. The majority of
cohort participants are older white male U.S. veterans and the results are therefore not gener-
alizable to other populations. This study relies on measurements of serum phosphorus level
obtained during routine medical care. Serum phosphorus concentration may be affected by
diurnal variation, dietary intake, fasting duration, and hormonal status [41]. Our datasets
did not include information on dietary phosphorus intake, urinary phosphate excretion, tim-
ing of blood draw, or levels of FGF-23. We relied on ICD-9 codes in defining major subtypes
of dementia and misclassification cannot be completely ruled out. Strengths of our study
include the use of large-scale health data, the use of validated definition of dementia, and
multiple sensitivity analyses to test the robustness of the association found in the primary
analysis [18].
In conclusion, the results of our study indicate that higher serum phosphorus levels, even if
in the normal range, are associated with increased risk of incident dementia, the association is
more robust in those younger than 60 years old. Our results need to be validated in other
cohorts and in the general population. Clinical investigation is needed to evaluate whether die-
tary interventions aimed at reducing serum phosphorus levels will ameliorate the risk of
dementia. Furthermore, additional experimental studies are needed to elucidate a putative
mechanism(s) underpinning the association between phosphorus and dementia.
Phosphorus and dementia
PLOS ONE | DOI:10.1371/journal.pone.0171377 February 2, 2017 15 / 19
Supporting information
S1 Table. Relationship between serum phosphorus (in quintiles) and risk of incident
dementia by age group (60, >60 and70, and >70).
(DOCX)
Acknowledgments
Support for VA/Centers for Medicare and Medicaid Services (CMS) data is provided by the
Department of Veterans Affairs, Veterans Health Administration, Office of Research and




Data curation: YX BB.
Formal analysis: TL YX BB.
Funding acquisition: ZAA.
Investigation: TL YX ZAA.
Methodology: TL YX BB HX ZAA.
Project administration: ZAA.
Resources: YX BB ZAA.
Software: YX BB.
Supervision: ZAA.
Validation: TL YX BB HX ZAA.
Visualization: TL YX BB HX ZAA.
Writing – original draft: TL ZAA.
Writing – review & editing: TL YX BB HX ZAA.
References
1. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an
occult burden. Advances in chronic kidney disease. 2008; 15(2):123–32. Epub 2008/03/13. doi: 10.
1053/j.ackd.2008.01.010 PMID: 18334236
2. Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of Dementia over
Three Decades in the Framingham Heart Study. New England Journal of Medicine. 2016; 374(6):523–
32. doi: 10.1056/NEJMoa1504327 PMID: 26863354
3. Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence
declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012; 78
(19):1456–63. Epub 2012/05/04. doi: 10.1212/WNL.0b013e3182553be6 PMID: 22551732
4. Bugnicourt JM, Godefroy O, Chillon JM, Choukroun G, Massy ZA. Cognitive disorders and dementia in
CKD: the neglected kidney-brain axis. J Am Soc Nephrol. 2013; 24(3):353–63. Epub 2013/01/08. doi:
10.1681/ASN.2012050536 PMID: 23291474
5. Seliger SL, Siscovick DS, Stehman-Breen CO, Gillen DL, Fitzpatrick A, Bleyer A, et al. Moderate renal
impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J Am
Soc Nephrol. 2004; 15(7):1904–11. Epub 2004/06/24. PMID: 15213280
Phosphorus and dementia
PLOS ONE | DOI:10.1371/journal.pone.0171377 February 2, 2017 16 / 19
6. Khatri M, Nickolas T, Moon YP, Paik MC, Rundek T, Elkind MS, et al. CKD associates with cognitive
decline. Journal of the American Society of Nephrology: JASN. 2009; 20(11):2427–32. doi: 10.1681/
ASN.2008101090 PMID: 19729443
7. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocyste-
ine lowering and cognitive performance. The New England journal of medicine. 2006; 354(26):2764–
72. doi: 10.1056/NEJMoa054025 PMID: 16807413
8. Toyoda K. Cerebral small vessel disease and chronic kidney disease. Journal of stroke. 2015; 17
(1):31–7. doi: 10.5853/jos.2015.17.1.31 PMID: 25692105
9. Murray AM BE, Knopman DS, Slinin Y, Foley RN, Tupper D. Risk Factors for Cognitive Impairment in
Chronic Kidney Disease—The Brain in Kidney Disease Study (ASN abstract TH-OR015). Journal of
American Society of Nephrology. 2015; 26.
10. Wright CB, Dong C, Stark M, Silverberg S, Rundek T, Elkind MS, et al. Plasma FGF23 and the risk of
stroke: the Northern Manhattan Study (NOMAS). Neurology. 2014; 82(19):1700–6. doi: 10.1212/WNL.
0000000000000410 PMID: 24706015
11. Wright CB, Shah NH, Mendez AJ, DeRosa JT, Yoshita M, Elkind MS, et al. Fibroblast Growth Factor 23
Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study. Stroke; a
journal of cerebral circulation. 2016.
12. Kim BJ, Lee SH. Prognostic Impact of Cerebral Small Vessel Disease on Stroke Outcome. Journal of
stroke. 2015; 17(2):101–10. doi: 10.5853/jos.2015.17.2.101 PMID: 26060797
13. Onufrak SJ, Bellasi A, Shaw LJ, Herzog CA, Cardarelli F, Wilson PW, et al. Phosphorus levels are asso-
ciated with subclinical atherosclerosis in the general population. Atherosclerosis. 2008; 199(2):424–31.
Epub 2007/12/21. doi: 10.1016/j.atherosclerosis.2007.11.004 PMID: 18093595
14. Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in com-
munity-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. American heart journal.
2008; 156(3):556–63. Epub 2008/09/02. doi: 10.1016/j.ahj.2008.05.016 PMID: 18760141
15. Murphy PA, Cowper DC, Seppala G, Stroupe KT, Hynes DM. Veterans Health Administration inpatient
and outpatient care data: an overview. Effective clinical practice: ECP. 2002; 5(3 Suppl):E4. PMID:
12166925
16. Oddone EZ, Eisen S. Veterans Affairs Research and Development: using science to improve health
care for veterans. North Carolina medical journal. 2008; 69(1):35–7. PMID: 18429564
17. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and
renal phosphate handling in healthy young men. The Journal of clinical endocrinology and metabolism.
2005; 90(3):1519–24. doi: 10.1210/jc.2004-1039 PMID: 15613425
18. St Germaine-Smith C, Metcalfe A, Pringsheim T, Roberts JI, Beck CA, Hemmelgarn BR, et al. Recom-
mendations for optimal ICD codes to study neurologic conditions: a systematic review. Neurology.
2012; 79(10):1049–55. doi: 10.1212/WNL.0b013e3182684707 PMID: 22914826
19. Bharmal MF, Weiner M, Sands LP, Xu H, Craig BA, Thomas J 3rd. Impact of patient selection criteria
on prevalence estimates and prevalence of diagnosed dementia in a Medicaid population. Alzheimer
disease and associated disorders. 2007; 21(2):92–100. doi: 10.1097/WAD.0b013e31805c0835 PMID:
17545733
20. Bowe B, Xie Y, Xian H, Balasubramanian S, M AZ, Al-Aly Z. High Density Lipoprotein Cholesterol and
the Risk of All-Cause Mortality among U.S. Veterans. Clinical journal of the American Society of
Nephrology: CJASN. 2016.
21. Bowe B XY, Xian H, Lian M, Al-Aly Z. Geographic Variation and US County Characteristics Associated
with Rapid Kidney Function Decline. Kidney International Reports. 2016.
22. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z. Estimated GFR Trajectories of People Entering
CKD Stage 4 and Subsequent Kidney Disease Outcomes and Mortality. American journal of kidney dis-
eases: the official journal of the National Kidney Foundation. 2016.
23. Bowe B, Xie Y, Xian H, Balasubramanian S, Al-Aly Z. Low levels of high-density lipoprotein cholesterol
increase the risk of incident kidney disease and its progression. Kidney international. 2016; 89(4):886–
96. doi: 10.1016/j.kint.2015.12.034 PMID: 26924057
24. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton Pump Inhibitors and Risk of Incident
CKD and Progression to ESRD. Journal of the American Society of Nephrology: JASN. 2016.
25. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z. Rate of Kidney Function Decline and Risk of Hos-
pitalizations in Stage 3A CKD. Clinical journal of the American Society of Nephrology: CJASN. 2015; 10
(11):1946–55. doi: 10.2215/CJN.04480415 PMID: 26350437
26. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z. Renal Function Trajectories in Patients with Prior
Improved eGFR Slopes and Risk of Death. PloS one. 2016; 11(2):e0149283. doi: 10.1371/journal.
pone.0149283 PMID: 26900691
Phosphorus and dementia
PLOS ONE | DOI:10.1371/journal.pone.0171377 February 2, 2017 17 / 19
27. Al-Aly Z, Balasubramanian S, McDonald JR, Scherrer JF, O’Hare AM. Greater variability in kidney func-
tion is associated with an increased risk of death. Kidney international. 2012; 82(11):1208–14. doi: 10.
1038/ki.2012.276 PMID: 22854642
28. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to esti-
mate glomerular filtration rate. Annals of internal medicine. 2009; 150(9):604–12. PMID: 19414839
29. Jason P. Fine RJG. A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal
of the American Statistical Association 1999; Vol. 94(No. 446):496–509
30. Calvo MS, Park YK. Changing phosphorus content of the U.S. diet: potential for adverse effects on
bone. The Journal of nutrition. 1996; 126(4 Suppl):1168s–80s. Epub 1996/04/01. PMID: 8642452
31. Chang AR, Lazo M, Appel LJ, Gutierrez OM, Grams ME. High dietary phosphorus intake is associated
with all-cause mortality: results from NHANES III. The American journal of clinical nutrition. 2014; 99
(2):320–7. Epub 2013/11/15. doi: 10.3945/ajcn.113.073148 PMID: 24225358
32. Leon JB, Sullivan CM, Sehgal AR. The prevalence of phosphorus-containing food additives in top-sell-
ing foods in grocery stores. Journal of renal nutrition: the official journal of the Council on Renal Nutrition
of the National Kidney Foundation. 2013; 23(4):265–70.e2. Epub 2013/02/14.
33. Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in
nephrology? Seminars in dialysis. 2003; 16(3):186–8. Epub 2003/05/20. PMID: 12753675
34. Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM. Effects of die-
tary phosphate and calcium intake on fibroblast growth factor-23. Clinical journal of the American Soci-
ety of Nephrology: CJASN. 2011; 6(2):383–9. doi: 10.2215/CJN.04730510 PMID: 21030580
35. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of C-termi-
nal and intact FGF-23 by dietary phosphate in men and women. Journal of bone and mineral research:
the official journal of the American Society for Bone and Mineral Research. 2006; 21(8):1187–96.
36. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-
23 concentrations in healthy men. The Journal of clinical endocrinology and metabolism. 2006; 91
(8):3144–9. doi: 10.1210/jc.2006-0021 PMID: 16735491
37. Relph WL. Addressing the nutritional needs of older patients. Nursing older people. 2016; 28(3):16–9.
Epub 2016/04/01. doi: 10.7748/nop.28.3.16.s22 PMID: 27029988
38. Dorner B, Friedrich EK, Posthauer ME. Position of the American Dietetic Association: individualized
nutrition approaches for older adults in health care communities. Journal of the American Dietetic Asso-
ciation. 2010; 110(10):1549–53. Epub 2010/10/05. PMID: 20882714
39. Sanders C, Behrens S, Schwartz S, Wengreen H, Corcoran CD, Lyketsos CG, et al. Nutritional Status
is associated with Faster Cognitive Decline and Worse Functional Impairment in the Progression of
Dementia: The Cache County Dementia Progression Study1. Journal of Alzheimer’s disease: JAD.
2016. Epub 2016/03/12.
40. Spaccavento S, Del Prete M, Craca A, Fiore P. Influence of nutritional status on cognitive, functional
and neuropsychiatric deficits in Alzheimer’s disease. Archives of gerontology and geriatrics. 2009; 48
(3):356–60. Epub 2008/05/02. doi: 10.1016/j.archger.2008.03.002 PMID: 18448178
41. Yoo KD, Kang S, Choi Y, Yang SH, Heo NJ, Chin HJ, et al. Sex, Age, and the Association of Serum
Phosphorus With All-Cause Mortality in Adults With Normal Kidney Function. American journal of kid-
ney diseases: the official journal of the National Kidney Foundation. 2016; 67(1):79–88. Epub 2015/09/
06.
42. Dhingra R, Sullivan LM, Fox CS, et al. RElations of serum phosphorus and calcium levels to the inci-
dence of cardiovascular disease in the community. Archives of Internal Medicine. 2007; 167(9):879–85.
doi: 10.1001/archinte.167.9.879 PMID: 17502528
43. Chang AR, Grams ME. Serum phosphorus and mortality in the Third National Health and Nutrition
Examination Survey (NHANES III): effect modification by fasting. American journal of kidney diseases:
the official journal of the National Kidney Foundation. 2014; 64(4):567–73. Epub 2014/06/18.
44. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G, Cholesterol ft, et al. Relation Between Serum Phos-
phate Level and Cardiovascular Event Rate in People With Coronary Disease. Circulation. 2005; 112
(17):2627–33. doi: 10.1161/CIRCULATIONAHA.105.553198 PMID: 16246962
45. Reis JP, Launer LJ, Terry JG, Loria CM, Zeki Al Hazzouri A, Sidney S, et al. Subclinical atherosclerotic
calcification and cognitive functioning in middle-aged adults: the CARDIA study. Atherosclerosis. 2013;
231(1):72–7. Epub 2013/10/16. doi: 10.1016/j.atherosclerosis.2013.08.038 PMID: 24125414
46. Breteler MM, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive
function in elderly people: the Rotterdam Study. BMJ (Clinical research ed). 1994; 308(6944):1604–8.
Epub 1994/06/18.
47. Breteler MM. Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiology
of aging. 2000; 21(2):153–60. Epub 2000/06/27. PMID: 10867200
Phosphorus and dementia
PLOS ONE | DOI:10.1371/journal.pone.0171377 February 2, 2017 18 / 19
48. Breteler MM. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the
Rotterdam Study and the Rotterdam Scan Study. Annals of the New York Academy of Sciences. 2000;
903:457–65. Epub 2000/05/20. PMID: 10818538
49. de la Torre JC. Vascular basis of Alzheimer’s pathogenesis. Annals of the New York Academy of Sci-
ences. 2002; 977:196–215. Epub 2002/12/14. PMID: 12480752
50. Gutierrez OM. The connection between dietary phosphorus, cardiovascular disease, and mortality:
where we stand and what we need to know. Advances in nutrition (Bethesda, Md). 2013; 4(6):723–9.
Epub 2013/11/15.
51. Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato M, et al. Dietary phosphorus acutely impairs
endothelial function. J Am Soc Nephrol. 2009; 20(7):1504–12. Epub 2009/05/02. doi: 10.1681/ASN.
2008101106 PMID: 19406976
52. Watari E, Taketani Y, Kitamura T, Tanaka T, Ohminami H, Abuduli M, et al. Fluctuating plasma phos-
phorus level by changes in dietary phosphorus intake induces endothelial dysfunction. Journal of clinical
biochemistry and nutrition. 2015; 56(1):35–42. Epub 2015/02/14. doi: 10.3164/jcbn.14-96 PMID:
25678749
53. Abbasian N, Burton JO, Herbert KE, Tregunna BE, Brown JR, Ghaderi-Najafabadi M, et al. Hyperpho-
sphatemia, Phosphoprotein Phosphatases, and Microparticle Release in Vascular Endothelial Cells. J
Am Soc Nephrol. 2015; 26(9):2152–62. Epub 2015/03/07. doi: 10.1681/ASN.2014070642 PMID:
25745026
54. Dursun I, Poyrazoglu HM, Gunduz Z, Ulger H, Yykylmaz A, Dusunsel R, et al. The relationship between
circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic
kidney disease. Nephrology, dialysis, transplantation: official publication of the European Dialysis and
Transplant Association—European Renal Association. 2009; 24(8):2511–8. Epub 2009/02/27.
Phosphorus and dementia
PLOS ONE | DOI:10.1371/journal.pone.0171377 February 2, 2017 19 / 19
